A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Food Effect of Single Ascending Doses and Multiple Ascending Doses of EHP-101 in Healthy Subjects
Overview
- Phase
- Phase 1
- Intervention
- EHP-101 Liquid single dose
- Conditions
- Healthy
- Sponsor
- Emerald Health Pharmaceuticals
- Enrollment
- 104
- Locations
- 1
- Primary Endpoint
- Number of participants with treatment emergent adverse events (TEAEs) including serious adverse events (SAEs) following single and multiple ascending oral doses for 30 days after dosing.
- Status
- Completed
- Last Updated
- 6 years ago
Overview
Brief Summary
The study will assess the safety and tolerability, pharmacodynamic, pharmacokinetic profiles, and food effect of single ascending doses and multiple ascending doses (7 consecutive days) after daily oral administration in healthy male and female subjects.
Detailed Description
This Phase 1, single center, randomized, double-blind, placebo-controlled study will be conducted in 2 parts: the single ascending dosing (SAD) will constitute Part 1 and the multiple ascending dosing (MAD) will constitute Part 2. In Part 1 (ie, SAD) of the study, up to 64 eligible subjects will be randomized with an allocation ratio of 3:1 to receive EHP-101 Liquid or matching placebo within one of up to 8 sequential cohorts; Sentinel subjects (1 receiving EHP-101 Liquid and 1 receiving placebo) will be dosed prior to dosing the remaining 6 subjects to allow for observation of adverse reactions before exposing the Investigational Product (IP) to a greater number of subjects, in the SAD cohorts. In Part 2 of the study, up to 40 eligible subjects will be randomized with an allocation ratio of 4:1 to receive EHP 101 Liquid or matching placebo within one of up to 4 cohorts. Dose-escalations, initiation of a single-dose food effect cross-over investigation and the start of the MAD part of the study will be coordinated by a Safety Review Committee (SRC) following review of available safety data.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Healthy male or female subjects ≥ 18 to ≤ 65 years of age.
- •Body mass index (BMI) range 18 to 34 kg/m².
- •Free from any clinically significant abnormality on the basis of medical history, vital signs, physical examination, 12-lead electrocardiogram (ECG), echocardiography, ophthalmologic examinations and tests, and laboratory evaluations at screening and admission, as judged by the Investigator.
- •Cardiac Troponin I level below the upper limit of normal, as defined by the manufacturer.
- •Ability to understand and the willingness to provide informed consent for participation in the study.
- •Ability and willingness, as judged by the Investigator, to comply with all study requirements.
Exclusion Criteria
- •Any known, documented, or suspected history of:
- •schizophrenia or other psychotic illness, or diagnosis of schizophrenia in a first-degree relative.
- •alcohol or substance abuse within the last 2 years before screening or positive test result(s) for alcohol and or drugs of abuse.
- •Regular alcohol consumption \>21 units per week
- •Use of nicotine or nicotine-containing products during participation in the study.
- •Caffeine consumption is limited to no more than 2 units per day.
- •Any known, documented, or suspected hypersensitivity to cannabinoids or any of the excipients of EHP-101 Liquid.
- •Use of cannabis or cannabinoid-based medications.
- •Abnormal screening 12-lead ECG interpreted by the Investigator to be clinically significant.
- •Presence of ophthalmologic abnormalities at baseline, specifically known closed angles, previous laser iridotomy, or severe hypermetropic diagnosis.
Arms & Interventions
Single dose study part
there will be 7 cohorts of healthy volunteers dosed with single doses of EHP-101 (7 planned dose levels) or with placebo and 1 potential additional cohort (also dosed with single dose of EHP-101 or placebo)
Intervention: EHP-101 Liquid single dose
Single dose study part
there will be 7 cohorts of healthy volunteers dosed with single doses of EHP-101 (7 planned dose levels) or with placebo and 1 potential additional cohort (also dosed with single dose of EHP-101 or placebo)
Intervention: Matching placebo
Multiple dose study part
there will be 3 cohorts of healthy volunteers dosed with multiple doses of EHP-101 (3 planned dose levels) or placebo and 1 potential additional cohort (also dosed with multiple doses of EHP-101 or placebo)
Intervention: EHP-101 Liquid multiple doses
Multiple dose study part
there will be 3 cohorts of healthy volunteers dosed with multiple doses of EHP-101 (3 planned dose levels) or placebo and 1 potential additional cohort (also dosed with multiple doses of EHP-101 or placebo)
Intervention: Matching placebo
Outcomes
Primary Outcomes
Number of participants with treatment emergent adverse events (TEAEs) including serious adverse events (SAEs) following single and multiple ascending oral doses for 30 days after dosing.
Time Frame: From the time of the first dose and continued until 30 days after
This safety outcome combines the measure of the number of subjects experiencing adverse events (AEs), the nature and severity of those AEs and their relationship to the study treatments.
Secondary Outcomes
- Time to reach VCE-004.8 maximum concentration after a single drug administration (Tmax).(Starting 1 hour prior to dosing on Day 1 and until 192 hours after dosing on Day 9.)
- Area under the serum VCE-004.8 concentration-time curve from time zero to the time of last quantifiable concentration (AUClast) after the first dose administration during multiple drug administration(Starting 1 hour prior the first dose administration (Day 1) until 120 hours after the first dose administration on Day 12)
- The accumulation VCE-004.8 ratio (Racc) after multiple drug administration(Starting 1 hour prior the first dose administration (Day 1) until 120 hours after the last dose administration on Day 12.)
- Observed maximum VCE-004.8 serum concentration following single drug administration (Cmax).(Starting 1 hour prior to dosing on Day 1 and until 192 hours after dosing on Day 9.)
- Area under the serum VCE-004.8 concentration-time curve from time zero to the time of last quantifiable concentration (AUClast) following single drug administration.(Starting 1 hour prior to dosing on Day 1 and until 192 hours after dosing on Day 9.)
- Time to reach VCE-004.8 maximum concentration after a multiple drug administration (Tmax).(Starting 1 hour prior the first dose administration (Day 1) until 120 hours after the last dose administration on Day 12)
- Observed maximum VCE-004.8 serum concentration following multiple drug administration (Cmax).(Starting 1 hour prior the first dose administration (Day 1) until 24 hours after the first dose administration on Day 8)
- Observed maximum VCE-004.8 serum concentration following drug administration at steady state (Cmax,ss) after multiple drug administration(Starting 1 hour prior the first dose administration (Day 1) until 120 hours after the first dose administration on Day 12)
- The area under the serum VCE-004.8 concentration-time curve from time zero to the end of the dosing interval tau at steady state (AUCtau,ss) during multiple drug administration(Starting 1 hour prior the first dose administration (Day 1) until 120 hours after the last dose administration on Day 12.)
- The average steady state VCE-004.8 serum concentration during multiple dosing (Cav,ss) after multiple dose administration(Starting 1 hour prior the first dose administration (Day 1) until 120 hours after the last dose administration on Day 12.)
- The effective VCE-004.8 half-life based on drug accumulation at steady state (T1/2,acc) after multiple dose administration(Starting 1 hour prior the first dose administration (Day 1) until 120 hours after the last dose administration on Day 12.)